JACKSONVILLE, Fla.--(BUSINESS WIRE)--NovaBone Products, a leading biologics medical device company, today announces that the U.S. Patent and Trademark Office (USPTO) has issued notice of allowance for U.S. Patent application 14188-54 for its "Combination Products Including Bioactive Glass and Collagen and Kits Including the
“Our R&D pipeline is robust while we have continued to develop novel dispensing devices designed for surgeon’s specific needs.”Tweet this
"This patent expands the portfolio of bioactive glass/collagen patents to include the use of porous and non-porous bioactive glass, as well as various particle sizes," said Greg Pomrink, Vice President, Research and Development. "This is important because it allows us to engineer the speed of bone healing and the rate of resorption of the bone graft,” he added.
When this patent issues in December, it will mark the fourth new patent issued to NovaBone Products since August 2014.
"I am very pleased with the progress our team has made in establishing Novabone as the leader in bioactive glass/collagen composite technology,” said Art Wotiz, President of NovaBone Products. “Our R&D pipeline is robust while we have continued to develop novel dispensing devices designed for surgeon’s specific needs.”
All of NovaBone’s devices are developed and made in its state-of-the art manufacturing facility in Alachua, Florida. In total, NovaBone Products produces seven devices within the field of orthopedics with unparalleled versatility and the widest range of choices in the bone graft device market. For more information about NovaBone's newest orthopedic devices: http://www.novabone.com/ortho/index.htm.
NovaBone is a privately held company based in Florida, USA since 2002. NovaBone developed the first bioactive synthetic bone graft offered to the orthopedic community and has long been at the forefront of bioactive glass bone graft devices. With ongoing development of collagen devices and bioactive glass/collagen devices, the company continues to keep step with demand for improved graft devices and delivery systems.
A Notice of Allowance is issued after the USPTO makes a determination that claims in a patent application are deemed to represent patentable subject matter.